-
<![CDATA[Sleep doctor convicted in insurer fraud, tax evasion; most commercially insured patients now live with chronic disease; the most anticipated drug launches of 2026 – Morning Medical Update]]>
03 Feb 2026 10:14 GMT
… by billing an insurer for treating his brother and, after being … .
The most anticipated drug launches of 2026
Fierce Pharma released its annual … and diabetes drugs, with additional entries spanning oncology, immunology, neurology, hypertension and …
-
<![CDATA[FDA Accepts NDA for Zanzalintinib/Atezolizumab in Pretreated Metastatic CRC]]>
03 Feb 2026 00:30 GMT
… president of research and development at Exelixis, stated … treatment option for heavily pretreated patients with metastatic CRC.”
Trial … combination included diarrhea (50%), hypertension (34%), fatigue (33%), … U.S. FDA acceptance of New Drug Application for …
-
<![CDATA[FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC]]>
02 Feb 2026 20:17 GMT
… president of Research and Development at Exelixis, in a … advancement in a challenging treatment landscape, and if approved … across both arms included diarrhea, hypertension, fatigue, nausea, and … U.S. FDA accepted the new drug application for zanzalintinib …
-
February is Tinnitus Awareness Month – what is it, and how can I treat it?
02 Feb 2026 19:53 GMT
… medical conditions that include hypertension (high blood pressure), … Ironically, several hundred drugs listed in the … prescribed medication, always inform your physician and pharmacist of … NeuroTechnology™. The FDA has approved treatment for individuals with …
-
<![CDATA[FDA Accepts NDA for Rivoceranib and Camrelizumab in 1L Unresectable HCC]]>
02 Feb 2026 18:12 GMT
… FDA requested more information on the treatment. The developer … phase 3 CARES-310 trial (NCT03764293), which … treatment-related adverse events (TRAEs) in the combination arm included hypertension … News release. Jiangsu Hengrui Pharmaceuticals Co Ltd. May …
-
Peripheral Artery Disease Market Size To Reach USD 8.65 Billion By 2033, Driven By The Aging Population And The Development Of Endovascular Technologies SNS Insider.
02 Feb 2026 16:27 GMT
… hypertension, drive disease progression and increase demand for treatment … Resuming levels of drug-eluting stents, atherectomy … Developments: In February 2025, Abbott received FDA … shifts in treatment preference. INTERVENTIONAL VS PHARMACOLOGICAL ADOPTION RATE …
-
Natural solutions to hypertension: How beets, garlic and leafy greens can lower blood pressure without Big Pharma’s toxic drugs
02 Feb 2026 15:21 GMT
… or matching pharmaceutical drugs.
Blood pressure medications often come with … 8 mmHg drops, rivaling drug efficacy.
Garlic (mimics … their risk of developing hypertension by 37%. Unlike Big Pharma';s … drugs in clinical trials.
Why do doctors push pills …
-
Peripheral Artery Disease Market Size to Reach USD 8.65 Billion by 2033, Driven by the Aging Population and the Development of Endovascular Technologies – SNS Insider.
02 Feb 2026 15:04 GMT
… hypertension, drive disease progression and increase demand for treatment … Resuming levels of drug-eluting stents, atherectomy … Developments:
In February 2025, Abbott received FDA … shifts in treatment preference.
INTERVENTIONAL VS PHARMACOLOGICAL ADOPTION RATE …
-
FDA Warned Corcept of ‘Significant Review Issues’ for Rejected Drug in Early Meetings
02 Feb 2026 14:59 GMT
… agonist relacorilant for the treatment of hypercortisolism, a verdict … development program to assess the effect of relacorilant on hypertension … GRACE study showed the drug aced its key endpoint, … the proposed indication,” the FDA wrote.
Moving forward, Corcept …
-
Development and Validation of a Nomogram for Predicting Response to TACE Combined with Lenvatinib and Anti-PD-1 Therapy in Unresectable Hepatocellular Carcinoma
02 Feb 2026 13:58 GMT
… , age, hypertension, diabetes, hepatitis, cirrhosis, antiviral treatment, Child-Pugh …
Systemic Therapy
All medications were administered according to … promoting revascularization and the development of collateral circulation, … . Eur J Clin Pharmacol. 2023;79(7 …
About
© 1995-2026